Search details
1.
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Int J Cancer
; 144(4): 877-885, 2019 02 15.
Article
in English
| MEDLINE | ID: mdl-29992557
2.
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Breast Care (Basel)
; 19(1): 1-9, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38384488
3.
Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
Anticancer Res
; 41(1): 485-496, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33419847
4.
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
J Bone Oncol
; 14: 010-10, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30515367
5.
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
Onkologie
; 30(8-9): 450-1, 2007 Sep.
Article
in English
| MEDLINE | ID: mdl-17848817
6.
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Haematologica
; 94(1): 141-4, 2009 Jan.
Article
in English
| MEDLINE | ID: mdl-19029146
Results
1 -
6
de 6
1
Next >
>>